A US judge in Missouri has approved German chemical giant Bayer's $7.25 billion (€6.60 billion) settlement of lawsuits alleging that its Roundup weedkiller causes cancer, a decision that could help end years of costly litigation inherited when Bayer bought Monsanto in 2018. The agreement covers tens of thousands of people who say they developed non-Hodgkin lymphoma after using Roundup, as well as those who may be diagnosed in the future after earlier exposure. Some plaintiff lawyers have criticized the payments as too low, but the judge rejected their objections, saying further delays could leave seriously ill patients waiting years for compensation.
Key Takeaways: Judge Timothy Boyer ruled the agreement "fair, reasonable, and adequate"; Bayer will pay up to $7.25 billion into a special fund over 21 years; individual payments are expected to average between $10,000 and $165,000. The settlement also covers future diagnoses after previous exposure and marks a major step in resolving roughly 200,000 claims linked to Roundup.
Bayer inherited Roundup's legal troubles through its $63 billion acquisition of Monsanto in 2018. Monsanto introduced Roundup in 1974, and its active ingredient, glyphosate, became one of the world's most widely used weedkillers, applied by farmers to kill weeds without harming genetically modified crops and widely used in private gardens and lawns. Since the takeover, about 200,000 claims have been filed by people who believe the weedkiller caused their cancer. Bayer reached a $10.9 billion settlement in 2020 but failed to secure approval for a separate agreement covering future cases. Some lawsuits produced large awards, including a $2.1 billion verdict for plaintiffs in Georgia. The company has set aside $16 billion for Roundup-related legal costs, and its shares have fallen 46 percent since the Monsanto deal. Bayer has also removed glyphosate from newer versions of Roundup sold to private consumers in the United States.
Bayer CEO Bill Anderson said the court's final approval is a decisive milestone in the company's strategy to mitigate risks from both pending and future Roundup litigation. Christopher Seeger, a lawyer representing cancer patients, welcomed the ruling, saying it delivers guaranteed compensation to Roundup cancer victims who have waited more than a decade for justice. The judge dismissed objections that payments were too low, arguing that delays could leave seriously ill patients waiting years. Bayer has also said it removed glyphosate from newer consumer versions of Roundup in the US.
The settlement follows a major June victory for Bayer at the US Supreme Court, which ruled that the company could not be sued under state laws for failing to put cancer warnings on Roundup packaging because federal rules did not require such warnings and states could not impose additional labeling requirements. That decision made it much harder for cancer patients to win lawsuits against Bayer. In October, a Missouri jury also ruled in Bayer's favor in a separate Roundup cancer case. However, about 200 cases are still being fought in federal courts outside the new settlement, according to Bayer. The ruling could still be appealed, leaving final payout timing and costs uncertain. Scientists and regulators continue to disagree over whether glyphosate causes cancer, a dispute that could fuel further litigation and scientific debate.
Source: www.dw.com